Gut microbiota: Mining for therapeutic potential

Typeset version

 

TY  - JOUR
  - O'Hara, A. M.,Shanahan, F.
  - 2007
  - March
  - Clinical Gastroenterology and Hepatology
  - Gut microbiota: Mining for therapeutic potential
  - Validated
  - ()
  - 5
  - 33
  - 274
  - 284274
  - The resident microbiota of the human intestine exerts a conditioning effect on intestinal homeostasis, delivering regulatory signals to the epithelium and instructing mucosal immune responses. Pattern recognition receptors are key mediators of innate host defense, and in healthy individuals, the mucosal immune system exhibits an exquisitely regulated restrained response to the resident microbiota. However, in genetically susceptible hosts, unrestrained mucosal immune activation in response to local bacterial signals can contribute to the pathogenesis of inflammatory bowel disease. Manipulation of the microbiota to enhance its beneficial components thus represents a potential therapeutic strategy for inflammatory bowel disease. Moreover, the microbiota might be a rich repository of metabolites that can be exploited for therapeutic benefit. Modern molecular techniques are facilitating improved understanding of host-microbe dialogue in health and in several disease processes, including inflammatory bowel disease. It follows that elucidating the molecular mechanisms of host-microbial interactions is now a prerequisite for a "bugs to drugs" program of discovery.The resident microbiota of the human intestine exerts a conditioning effect on intestinal homeostasis, delivering regulatory signals to the epithelium and instructing mucosal immune responses. Pattern recognition receptors are key mediators of innate host defense, and in healthy individuals, the mucosal immune system exhibits an exquisitely regulated restrained response to the resident microbiota. However, in genetically susceptible hosts, unrestrained mucosal immune activation in response to local bacterial signals can contribute to the pathogenesis of inflammatory bowel disease. Manipulation of the microbiota to enhance its beneficial components thus represents a potential therapeutic strategy for inflammatory bowel disease. Moreover, the microbiota might be a rich repository of metabolites that can be exploited for therapeutic benefit. Modern molecular techniques are facilitating improved understanding of host-microbe dialogue in health and in several disease processes, including inflammatory bowel disease. It follows that elucidating the molecular mechanisms of host-microbial interactions is now a prerequisite for a "bugs to drugs" program of discovery.
  - 1542-35651542-3565
  - ://WOS:000245400600005://WOS:000245400600005
DA  - 2007/03
ER  - 
@article{V235379287,
   = {O'Hara,  A. M. and Shanahan,  F. },
   = {2007},
   = {March},
   = {Clinical Gastroenterology and Hepatology},
   = {Gut microbiota: Mining for therapeutic potential},
   = {Validated},
   = {()},
   = {5},
   = {33},
  pages = {274--284274},
   = {{The resident microbiota of the human intestine exerts a conditioning effect on intestinal homeostasis, delivering regulatory signals to the epithelium and instructing mucosal immune responses. Pattern recognition receptors are key mediators of innate host defense, and in healthy individuals, the mucosal immune system exhibits an exquisitely regulated restrained response to the resident microbiota. However, in genetically susceptible hosts, unrestrained mucosal immune activation in response to local bacterial signals can contribute to the pathogenesis of inflammatory bowel disease. Manipulation of the microbiota to enhance its beneficial components thus represents a potential therapeutic strategy for inflammatory bowel disease. Moreover, the microbiota might be a rich repository of metabolites that can be exploited for therapeutic benefit. Modern molecular techniques are facilitating improved understanding of host-microbe dialogue in health and in several disease processes, including inflammatory bowel disease. It follows that elucidating the molecular mechanisms of host-microbial interactions is now a prerequisite for a "bugs to drugs" program of discovery.The resident microbiota of the human intestine exerts a conditioning effect on intestinal homeostasis, delivering regulatory signals to the epithelium and instructing mucosal immune responses. Pattern recognition receptors are key mediators of innate host defense, and in healthy individuals, the mucosal immune system exhibits an exquisitely regulated restrained response to the resident microbiota. However, in genetically susceptible hosts, unrestrained mucosal immune activation in response to local bacterial signals can contribute to the pathogenesis of inflammatory bowel disease. Manipulation of the microbiota to enhance its beneficial components thus represents a potential therapeutic strategy for inflammatory bowel disease. Moreover, the microbiota might be a rich repository of metabolites that can be exploited for therapeutic benefit. Modern molecular techniques are facilitating improved understanding of host-microbe dialogue in health and in several disease processes, including inflammatory bowel disease. It follows that elucidating the molecular mechanisms of host-microbial interactions is now a prerequisite for a "bugs to drugs" program of discovery.}},
  issn = {1542-35651542-3565},
   = {://WOS:000245400600005://WOS:000245400600005},
  source = {IRIS}
}
AUTHORSO'Hara, A. M.,Shanahan, F.
YEAR2007
MONTHMarch
JOURNAL_CODEClinical Gastroenterology and Hepatology
TITLEGut microbiota: Mining for therapeutic potential
STATUSValidated
TIMES_CITED()
SEARCH_KEYWORD
VOLUME5
ISSUE33
START_PAGE274
END_PAGE284274
ABSTRACTThe resident microbiota of the human intestine exerts a conditioning effect on intestinal homeostasis, delivering regulatory signals to the epithelium and instructing mucosal immune responses. Pattern recognition receptors are key mediators of innate host defense, and in healthy individuals, the mucosal immune system exhibits an exquisitely regulated restrained response to the resident microbiota. However, in genetically susceptible hosts, unrestrained mucosal immune activation in response to local bacterial signals can contribute to the pathogenesis of inflammatory bowel disease. Manipulation of the microbiota to enhance its beneficial components thus represents a potential therapeutic strategy for inflammatory bowel disease. Moreover, the microbiota might be a rich repository of metabolites that can be exploited for therapeutic benefit. Modern molecular techniques are facilitating improved understanding of host-microbe dialogue in health and in several disease processes, including inflammatory bowel disease. It follows that elucidating the molecular mechanisms of host-microbial interactions is now a prerequisite for a "bugs to drugs" program of discovery.The resident microbiota of the human intestine exerts a conditioning effect on intestinal homeostasis, delivering regulatory signals to the epithelium and instructing mucosal immune responses. Pattern recognition receptors are key mediators of innate host defense, and in healthy individuals, the mucosal immune system exhibits an exquisitely regulated restrained response to the resident microbiota. However, in genetically susceptible hosts, unrestrained mucosal immune activation in response to local bacterial signals can contribute to the pathogenesis of inflammatory bowel disease. Manipulation of the microbiota to enhance its beneficial components thus represents a potential therapeutic strategy for inflammatory bowel disease. Moreover, the microbiota might be a rich repository of metabolites that can be exploited for therapeutic benefit. Modern molecular techniques are facilitating improved understanding of host-microbe dialogue in health and in several disease processes, including inflammatory bowel disease. It follows that elucidating the molecular mechanisms of host-microbial interactions is now a prerequisite for a "bugs to drugs" program of discovery.
PUBLISHER_LOCATION
ISBN_ISSN1542-35651542-3565
EDITION
URL://WOS:000245400600005://WOS:000245400600005
DOI_LINK
FUNDING_BODY
GRANT_DETAILS